8-K ·Filed Jul 6, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonimmediate Processed2mo ago SEC0001104659-26-080562
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The ~$1.00 EPS headwind from this non-cash IPR&D charge is a one-time deal-related item, not an operational deterioration. Watch for the full Q2 2026 earnings release for underlying revenue and Dupixent/EYLEA HD trends — the charge will create a headline EPS miss vs the $8.47 Street consensus, but the core business trajectory (Q1 revenue +19% YoY, $3B buyback) remains intact. The prior Q1 filing showed strong momentum, so this pre-announcement is noise, not a signal change.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
REGN ▲ +15.50% at T+60d
NEUTRAL call ✓ call won +15.50% · α vs SPY +13.78% · entry $649.81 → $750.51
Entry anchored
Jul 2, 03:59 PM ET
via exchange tick
T+1d
+4.07%
call +4.07% · α +4.54%
$676.23
settled 3mo ago
T+5d
+2.26%
call +2.26% · α +1.78%
$664.52
settled 3mo ago
T+20d
+17.36%
call +17.36% · α +17.93%
$762.63
settled 2mo ago
T+60d
+15.50%
call +15.50% · α +13.78%
$750.51
settled 3d ago

Price Chart

Loading chart...

Executive Summary

Regeneron filed an 8-K pre-announcing an expected ~$127M pre-tax acquired IPR&D charge for Q2 2026, which will reduce GAAP and non-GAAP EPS by approximately $1.00 per diluted share. This is a non-cash charge tied to collaboration and licensing payments, not an operational deterioration, but it signals ongoing deal activity and will create a one-time headwind to reported Q2 earnings.

Key Facts

  • Regeneron expects a ~$127M pre-tax acquired IPR&D charge in Q2 2026 from collaboration and licensing up-front/opt-in payments.
  • The charge is expected to reduce GAAP and non-GAAP EPS by approximately $1.00 per diluted share in Q2 2026.
  • The charge is non-cash and deal-related, not an operational deterioration — Regeneron does not forecast such charges due to their uncertain timing.
  • Q2 2026 results are not yet finalized and remain subject to closing procedures.
  • The prior Q1 2026 quarter showed strong operational momentum: total revenue +19% YoY to $3.6B, non-GAAP EPS +15% to $9.47, and a new $3B buyback authorization.

Financial Impact

~$127M pre-tax IPR&D charge, ~$1.00 per diluted share negative impact on GAAP and non-GAAP EPS for Q2 2026

GAAP net income per diluted sharenon-GAAP net income per diluted share

Risk Factors

  • Q2 2026 GAAP and non-GAAP EPS will be reduced by ~$1.00 due to the IPR&D charge, potentially causing a headline miss vs consensus.
  • The charge is non-cash and deal-related, but momentum traders may react negatively to the EPS headwind.
  • Q2 results are not yet finalized — actuals could differ from the preliminary estimate.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (38 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-080562
Document: 0001104659-26-080562-index-headers.html0001104659-26-080562
Document: 0001104659-26-080562-index.html0001104659-26-080562
Document: 0001104659-26-080562.txt0001104659-26-080562
8-K Data (Synthetic)0001104659-26-080562
26 reports for REGN
Performance horizon
85% Hit rate 11 of 13 directional calls best @ T+60▲ +26.47%May 21, 2026
Filters
Rows
Reports for REGN — sortable, filterable
TypeNow
Oct 1, 2026
1d ago
ANALYST-UPGRADE
BULLISH ★ 4/10
—awaiting T+5——
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$843.47 $781.49▼ −7.35%▼ −6.20%$735.20 (−12.84%)
Aug 24, 2026
5w ago
Court Ruling
BULLISH ★ 5/10
$828.50 $799.08▼ −3.55%▼ −4.02%$735.20 (−11.26%)
Aug 20, 2026
6w ago
Press Release
NEUTRAL ★ 5/10
$826.64 $807.71▼ −2.29%▼ −3.40%$735.20 (−11.06%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$797.99 $840.84▲ +5.37%▲ +5.81%$735.20 (−7.87%)
Aug 11, 2026
7w ago
Court Ruling
BULLISH ★ 5/10
$797.00 $807.57▲ +1.33%▲ +1.73%$735.20 (−7.75%)
Jul 30, 2026
9w ago
8-K
BULLISH ★ 7/10
$738.34 $772.11▲ +4.57%▲ +0.95%$735.20 (−0.43%)
Jul 30, 2026
9w ago
Press Release
BULLISH ★ 7/10
$738.34 $772.11▲ +4.57%▲ +0.95%$735.20 (−0.43%)
Jul 27, 2026
9w ago
Press Release
BEARISH ★ 6/10
$695.18 $759.24▼ −9.21%▼ −6.95%$735.20 (−5.76%)
Jul 17, 2026
11w ago
Press Release
NEUTRAL ★ 3/10
$676.69 $651.91▼ −3.66%▼ −2.97%$735.20 (+8.65%)
Showing 10 of 26

US Market Status

Market Closed — Opens Mon (65h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access